Henry Schein Inc. (HSIC) Raised to “Buy” at Goldman Sachs Group Inc.
Goldman Sachs Group Inc. upgraded shares of Henry Schein Inc. (NASDAQ:HSIC) from a neutral rating to a buy rating in a report released on Tuesday. They currently have $185.00 price objective on the stock.
A number of other brokerages also recently issued reports on HSIC. Zacks Investment Research downgraded Henry Schein from a hold rating to a sell rating in a research report on Monday, August 8th. Bank of America Corp. initiated coverage on Henry Schein in a research note on Monday, September 12th. They set a buy rating and a $185.00 target price on the stock. Finally, Robert W. Baird reaffirmed an outperform rating and set a $176.00 target price (up previously from $175.00) on shares of Henry Schein in a research note on Tuesday, October 4th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $159.50.
Henry Schein (NASDAQ:HSIC) opened at 150.88 on Tuesday. Henry Schein has a 52 week low of $142.64 and a 52 week high of $183.00. The firm’s 50-day moving average price is $162.38 and its 200-day moving average price is $170.17. The stock has a market cap of $12.34 billion, a PE ratio of 25.56 and a beta of 1.05.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.01. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The business had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the business posted $1.46 earnings per share. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Equities analysts predict that Henry Schein will post $6.57 earnings per share for the current fiscal year.
In other Henry Schein news, Director Paul Brons sold 3,381 shares of the stock in a transaction on Monday, August 29th. The stock was sold at an average price of $164.03, for a total transaction of $554,585.43. Following the sale, the director now owns 13,715 shares of the company’s stock, valued at approximately $2,249,671.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.27% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Riverhead Capital Management LLC boosted its stake in shares of Henry Schein by 998.9% in the second quarter. Riverhead Capital Management LLC now owns 453,851 shares of the company’s stock valued at $80,241,000 after buying an additional 412,549 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Henry Schein by 55.7% in the second quarter. UBS Asset Management Americas Inc. now owns 802,401 shares of the company’s stock valued at $141,865,000 after buying an additional 286,976 shares during the period. Janus Capital Management LLC boosted its stake in shares of Henry Schein by 16.5% in the second quarter. Janus Capital Management LLC now owns 2,027,848 shares of the company’s stock valued at $358,522,000 after buying an additional 286,929 shares during the period. Virginia Retirement Systems ET AL bought a new stake in shares of Henry Schein during the second quarter valued at about $32,832,000. Finally, Bank of Montreal Can bought a new stake in shares of Henry Schein during the second quarter valued at about $32,344,000. 91.98% of the stock is currently owned by institutional investors and hedge funds.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.